← Leaderboards
Ali Naji
University Of Pennsylvania
$46,943,355
Attributed
$122,787,788
Total exposure
23
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $23.5M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$133,406,765 · 25
By mechanism
U01$86,762,258 · 5
UC4$17,818,862 · 1
U42$10,057,501 · 6
R01$7,191,901 · 5
P01$6,074,052 · 4
RC2$4,016,560 · 1
Top collaborators
- Klaus H. Kaestner17 shared
- Vijay Bhoj7 shared
- Alvin Carter Powers7 shared
- Mark A Atkinson6 shared
- James F Markmann6 shared
- Alfred L. Garfall5 shared
- Carl H. June5 shared
- Michael C. Milone5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Peter Philip Reese$11,077,710
- Klaus H. Kaestner$80,959,526
- David Seth Goldberg$7,222,905
- Michael Paul Cancro$14,117,755
- Mitchell A. Lazar$48,884,193
Others in their field
Top investigators on “Islet”
- Mark A Magnuson · Vanderbilt University$65,807,651
- Klaus H. Kaestner · University Of Pennsylvania$57,769,062
- Jeffrey P Krischer · University Of South Florida$55,786,141
- Joyce Carol Niland · City Of Hope/Beckman Research Institute$53,941,128
- William R Clarke · University Of Iowa$48,959,550
- Marian J. Rewers · University Of Colorado Denver$34,533,409
Research focus
IsletResearch PersonnelCellsInsulin-Dependent Diabetes MellitusT-LymphocytePhenotypePhysiologicalInsulinDiabetes MellitusIslets Of LangerhansPancreasBiologyUniversitiesTissuesCollaborationsProgramsBeta CellB-LymphocytesInsulin Dependent Diabetes MellitusFutureMetabolicModalityGenomicsImmunotherapy
Grant awards (86)
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$8,953,305
U01 · FY2025 · DK · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$4,303,502
U01 · FY2025 · AI · contact PI
Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D)$2,999,756
U01 · FY2025 · DK
Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D)$1,998,001
U01 · FY2025 · DK
Epitranscriptomics in human obesity and type 2 diabetes$1,972,780
RC2 · FY2025 · DK
Immune repertoire remodeling following B cell-targeted CAR T cells for induction of renal allograft tolerance in non-human primates$1,648,086
R01 · FY2025 · AI · contact PI
From Gut to Blood: Dissecting the mechanisms of CD4+ T cell pathology in islet autoimmunity across tissue environments.$810,781
R01 · FY2025 · DK
Engineering T cells to Promote Islet Transplant$771,158
R01 · FY2025 · DK
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$7,118,694
U01 · FY2024 · DK · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$3,825,129
U01 · FY2024 · AI · contact PI
The Human Pancreas Analysis Program for Type 2 Diabetes$2,880,000
U01 · FY2024 · DK
Epitranscriptomics in human obesity and type 2 diabetes$2,043,780
RC2 · FY2024 · DK
From Gut to Blood: Dissecting the mechanisms of CD4+ T cell pathology in islet autoimmunity across tissue environments.$805,444
R01 · FY2024 · DK
Engineering T cells to Promote Islet Transplant$774,236
R01 · FY2024 · DK
Fibroblast Activation Protein as a Potential Diagnostic and Therapeutic Target to Treat Chronic Allograft Dysfunction$365,625
R56 · FY2024 · AI
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$7,177,124
U01 · FY2023 · DK · contact PI
The Human Pancreas Analysis Program for Type 2 Diabetes$3,000,000
U01 · FY2023 · DK
Engineering T cells to Promote Islet Transplant$776,922
R01 · FY2023 · DK
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$764,364
U01 · FY2023 · AI · contact PI
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$50,565
U01 · FY2023 · DK · contact PI
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$7,234,411
U01 · FY2022 · DK · contact PI
The Human Pancreas Analysis Program for Type 2 Diabetes$3,000,000
U01 · FY2022 · DK
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2022 · AI · contact PI
Engineering T cells to Promote Islet Transplant$780,000
R01 · FY2022 · DK
The Human Pancreas Analysis Program for Type 2 Diabetes$268,247
U01 · FY2022 · DK
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D$7,333,457
U01 · FY2021 · DK · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2021 · AI · contact PI
Penn integrated Human Pancreas procurement and Analysis Program$5,569,273
UC4 · FY2020 · DK · contact PI
The Human Pancreas Analysis Program for Type 2 Diabetes$3,000,000
U01 · FY2020 · DK
The Human Pancreas Analysis Program for Type 2 Diabetes$940,000
U01 · FY2020 · DK
The Human Pancreas Analysis Program for Type 2 Diabetes$1,899,891
U01 · FY2019 · DK
Penn integrated Human Pancreas procurement and Analysis Program$12,249,589
UC4 · FY2016 · DK · contact PI
Targeting Blys/Baff in non-human primate islet transplantation$947,016
U01 · FY2016 · AI · contact PI
Targeting Blys/Baff in non-human primate islet transplantation$766,318
U01 · FY2015 · AI · contact PI
Targeting Blys/Baff in non-human primate islet transplantation$790,472
U01 · FY2014 · AI · contact PI
Targeting Blys/Baff in non-human primate islet transplantation$762,805
U01 · FY2013 · AI · contact PI
Targeting Blys/Baff in non-human primate islet transplantation$700,472
U01 · FY2012 · AI · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$1
U01 · FY2011 · DK · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$1
U01 · FY2010 · DK · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$1,681,007
U01 · FY2009 · DK · contact PI
ISOLATION AND DISTRIBUTION OF HIGH QUALITY HUMAN PANCREATIC ISLETS$972,017
U42 · FY2008 · RR · contact PI
Isolation and Distribution of high quality human pancreatic islets$924,736
U42 · FY2008 · RR · contact PI
Isolation and Distribution of high quality human pancreatic islets$47,281
U42 · FY2008 · RR · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$1
U01 · FY2008 · DK · contact PI
ISOLATION AND DISTRIBUTION OF HIGH QUALITY HUMAN PANCREATIC ISLETS$693,572
U42 · FY2007 · RR · contact PI
Isolation and Distribution of high quality human pancreatic islets$693,572
U42 · FY2007 · RR · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$1
U01 · FY2007 · DK · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$2,235,636
U01 · FY2006 · DK · contact PI
ISOLATION AND DISTRIBUTION OF HIGH QUALITY HUMAN PANCREATIC ISLETS$916,915
U42 · FY2006 · RR · contact PI
Isolation and Distribution of high quality human pancreatic islets$916,915
U42 · FY2006 · RR · contact PI
B Cell immunomodulation in islet transplantation$232,163
R33 · FY2006 · AI · contact PI
B-Lymphocyte Immunotherapy in Islet Transplantation$2,985,767
U01 · FY2005 · DK
ISOLATION AND DISTR ISLET CELLS: TYPE 1 DIABETES$1,174,868
U42 · FY2005 · RR
ISOLATION AND DISTR OF HIGH QUALITY HUMAN PANCRE*$834,868
U42 · FY2005 · RR
B Cell immunomodulation in islet transplantation$396,250
R33 · FY2005 · AI
ISOLATION AND DISTR OF HIGH QUALITY HUMAN PANCRE*$340,000
U42 · FY2005 · RR
TRANSPLANTATION OF ISOLATED PANCREATIC ISLETS TO TYPE I DIABETIC PATIENTS$5,795
M01 · FY2005 · RR
B-Lymphocyte Immunotherapy in Islet Transplantation$3,195,859
U01 · FY2004 · DK
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$932,573
P01 · FY2004 · DK
B Cell immunomodulation in islet transplantation$475,500
R33 · FY2004 · AI
ISOLATION AND DISTR OF HIGH QUALITY HUMAN PANCRE*$473,828
U42 · FY2004 · RR
ISOLATION AND DISTR ISLET CELLS: TYPE 1 DIABETES$473,828
U42 · FY2004 · RR
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$55,354
P01 · FY2004 · DK
Transplantation of Isolated Pancreatic Islets to Type I Diabetic Patients$10,298
M01 · FY2004 · RR
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$932,573
P01 · FY2003 · DK
ISOLATION AND DISTR OF HIGH QUALITY HUMAN PANCRE*$200,001
U42 · FY2003 · RR
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$53,741
P01 · FY2003 · DK
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$20,716
P01 · FY2003 · DK
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$932,573
P01 · FY2002 · DK
ISOLATION AND DISTR OF HIGH QUALITY HUMAN PANCRE*$640,100
U42 · FY2002 · RR
B CELLS AND AUTOIMMUNE DIABETES$193,199
R01 · FY2002 · DK
Peripheral Tolerance Mechanisms in NOD Diabetes$186,515
P01 · FY2002 · DK
Core--Islet Cell Facility$186,513
P01 · FY2002 · DK
B CELLS IN AUTOIMMUNE DIABETES$0
P01 · FY2002 · AI
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$932,573
P01 · FY2001 · DK
ISOLATION/DISTRIBUTION OF HUMAN PANCREATIC ISLETS$755,000
U42 · FY2001 · RR
B CELLS AND AUTOIMMUNE DIABETES$187,572
R01 · FY2001 · DK
Peripheral Tolerance Mechanisms in NOD Diabetes$186,515
P01 · FY2001 · DK
Core--Islet Cell Facility$186,513
P01 · FY2001 · DK
B CELLS IN AUTOIMMUNE DIABETES$0
P01 · FY2001 · AI
STRATEGIES FOR TREATMENT AND PREVENTION OF DIABETES$932,573
P01 · FY2000 · DK
AUTOIMMUNE DIABETES MATERNAL INNUNOGLOBULIN$262,394
R01 · FY2000 · HD
Peripheral Tolerance Mechanisms in NOD Diabetes$186,515
P01 · FY2000 · DK
Core--Islet Cell Facility$186,513
P01 · FY2000 · DK
B CELLS AND AUTOIMMUNE DIABETES$182,109
R01 · FY2000 · DK
B CELLS IN AUTOIMMUNE DIABETES$162,292
P01 · FY2000 · AI